Opel, N
Redlich, R
Kaehler, C
Grotegerd, D
Dohm, K
Heindel, W
Kugel, H
Thalamuthu, A
Koutsouleris, N
Arolt, V
Teuber, A
Wersching, H
Baune, B T
Berger, K
Dannlowski, U
Article History
Received: 19 October 2016
Revised: 25 January 2017
Accepted: 26 January 2017
First Online: 28 March 2017
Competing interests
: V Arolt is a member of advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Eli Lilly, Janssen-Organon, Lundbeck, Otsuka, Servier and Trommsdorff. These affiliations have no relevance to the work covered in the manuscript. The remaining authors declare no conflict of interest.